Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR Trial of LX102 vs aflibercept in neovascular age-related macular degeneration
ChiCTR2500115643Phase 3Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Dec 2025
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of LX102 in exudative macular degeneration (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Mean change in BCVA (letters) from baseline based on average at weeks 40 and 48. Started Dec 2025; status: recruiting.
02
Drugs
LX102
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2500115643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115643.